To clarify the role of IL10 and TGFβ1 on other immune counterparts, PBMCs from CLL patients were cultured with an anti-IL10 blocking antibody or the TGFβ type I receptor inhibitor (SB431542). This evidence concerns the gene TGFB1 and B-cell chronic lymphocytic leukemia.